Institute of Biosciences and Technology, Houston, Texas, USA and Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas, USA.
Address correspondence to: Robert Y.L. Tsai, Institute of Biosciences and Technology, Texas A&M University Health Science Center, 2121 W. Holcombe Blvd., Houston, Texas 77030, USA. Phone: 713.677.7690; Email: email@example.com.
First published December 11, 2017 - More info
See the related article at Cografting astrocytes improves cell therapeutic outcomes in a Parkinson’s disease model.
Most of the adult CNS lacks regenerative activity in terms of both neuron birth and neurite outgrowth. While this regeneration-unfriendly environment of the adult CNS may preserve the existing neuronal circuitry that takes years to develop in higher organisms, it also poses a major obstacle for CNS repair later in life. In this issue of the JCI, Song et al. report on their development of a strategy that uses region-specific and molecularly engineered astrocytes to turn an unfavorable brain environment into a favorable one for engrafted neural stem/progenitor cells (NSC/NPCs). In a rat model of Parkinson’s disease (PD), cografting NPCs with midbrain-derived astrocytes engineered to overexpress the transcription factors Nurr1 and Foxa2 promotes maturation and survival of the graft, resulting in therapeutic improvement. The results of this study raise the prospect of using modified astrocytes to improve the survival, maturation, and integration of engrafted NSC/NPCs as a restorative treatment for PD.
A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.
Click here to sign into your account.
Please select one of the subscription options, which includes a low-cost option just for this article.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Please try these troubleshooting tips.